Integrated analysis of safety data from 12 clinical interventional studies of plasma‐ and albumin‐free recombinant factor VIII (rAHF‐PFM) in haemophilia A

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|21|6|791-798

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.21, Iss.6, 2015-11, pp. : 791-798

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

By  

HAEMOPHILIA, Vol. 21, Iss. 2, 2015-03 ,pp. : 162-170

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 784-790

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 3, 2015-03 ,pp. : 360-369

John Wiley & Sons Inc

Access to resources Recommend Favorite

Factor VIII Inhibitors in Two Families with Mild Haemophilia A: Structural Analysis of the Mutations

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 30, Iss. 5, 2001-03 ,pp. : 268-279

Karger

Access to resources Recommend Favorite

Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 16, Iss. 1, 2018-01 ,pp. : 39-43

John Wiley & Sons Inc

Access to resources Recommend Favorite